---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-23-000186"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T20:41:13.638059+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Guardant Health Q3 revenue $143M (+22% YoY); raises FY 2023 guidance to $553-556M

## Summary
- GAAP net loss $86.1M ($0.73/share) vs $162M ($1.58) YoY; non-GAAP loss $79.2M ($0.67).
- Clinical test volume 43,900 (+35% YoY); biopharma tests 7,500 (+11%).
- Precision oncology revenue up 31% YoY; Medicare appeal payment of $3.6M included.
- FY 2023 revenue guidance raised to $553-556M (23-24% growth); cash $1.2B.
- Launched Guardant360 in Japan/China; Japan approval as CDx for ENHERTU.

## SEC filing metadata
- accession: 0001576280-23-000186
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000186/0001576280-23-000186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000186/gh-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-23-000186
- JSON: https://secwatch.observer/filing/0001576280-23-000186.json
- Plain text: https://secwatch.observer/filing/0001576280-23-000186.txt

## Key facts
- Earnings Releases
  Guardant Health, Inc. reported the quarter ended September 30, 2023 results: revenue $143.0 million, net income $86.1 million, EPS $0.73 per share. Guidance raised.
  - Period: the quarter ended September 30, 2023
  - Revenue: $143.0 million
  - Net income: $86.1 million
  - EPS: $0.73 per share
  - Guidance: raised
  - Result: reported results
  source text: tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights • Revenue of $143.0 million for the third quarter of 2023, an increase of 22% over the third quarter of 2022 • Reported 43,900 tests to clinical customers and 7,500 tests to biopharmaceutical customers in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000186/0001576280-23-000186-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.